A therosclerosis is associated with immune activation and with systemic immune responses and signs of inflammation. 1-3 Atherosclerotic plaques contain a large number of immune cells, particularly macrophages and T cells. 4, 5 Histopathological and clinical investigations point to immune activation of plaques as a cause of plaque rupture and acute coronary syndromes. Seroepidemiological studies suggest links between atherosclerosis and microbial infections. 6, 7 Animal studies have identified specific immune cells that play a role in atherogenesis. For example, congenital deficiency of macrophages, lymphocytes, and the Th 1 effector pathway, generated by cross-breeding apolipoprotein (apo) E knockout (KO) mice with op/op mutant mice, 8 recombinase acting gene-1 KO mice, 9 and interferon-␥ receptor KO mice, 10 respectively, have resulted in the reduction of aherosclerotic lesions. Furthermore, the blockade of c-fms, a receptor for macrophage colony stimulating factor, also caused marked suppression of atherogenesis in apo E-deficient mice, where macrophage differentiation was impaired. These and other studies suggest that immunomodulation may be used to treat or prevent atherosclerosis.
A therosclerosis is associated with immune activation and with systemic immune responses and signs of inflammation. [1] [2] [3] Atherosclerotic plaques contain a large number of immune cells, particularly macrophages and T cells. 4, 5 Histopathological and clinical investigations point to immune activation of plaques as a cause of plaque rupture and acute coronary syndromes. Seroepidemiological studies suggest links between atherosclerosis and microbial infections. 6, 7 Animal studies have identified specific immune cells that play a role in atherogenesis. For example, congenital deficiency of macrophages, lymphocytes, and the Th 1 effector pathway, generated by cross-breeding apolipoprotein (apo) E knockout (KO) mice with op/op mutant mice, 8 recombinase acting gene-1 KO mice, 9 and interferon-␥ receptor KO mice, 10 respectively, have resulted in the reduction of aherosclerotic lesions. Furthermore, the blockade of c-fms, a receptor for macrophage colony stimulating factor, also caused marked suppression of atherogenesis in apo E-deficient mice, where macrophage differentiation was impaired. These and other studies suggest that immunomodulation may be used to treat or prevent atherosclerosis.
Therapy with immunoglobulin has been used in the treatment of immune-mediated disorders for more than 25 years. [11] [12] [13] The mode of action of immunoglobulin is still unclear and may involve both Fc and V region-dependent mechanisms: blockade of Fc receptors on macrophages and effector cells, antiinflammatory effects by attenuation of complement-mediated damage, regulation of the production of cytokines, or inhibition of lymphocyte proliferation. Several of these mechanisms might be beneficial in atherosclerosis. 14 Indeed, we have found that immunoglobulin therapy markedly suppressed atherosclerosis because of Fc receptormediated immunomodulatory actions in apoE-deficient mice. 15 In the present issue of Circulation Research, Hernández-Vargas et al report that Fc␥ receptor deficiency protects against the development of atherosclerosis in apo E KO mice. 16 Using double knock out (DKO) mice by crossing apo E KO mice with IgG Fc receptors (Fc␥Rs) deficient mice, they demonstrated that DKO mice exhibited a reduction in the atherosclerotic lesion size compared with apoE KO, control mice without alterations in serum lipid profiles. Fc␥R deficiency in DKO mice significantly diminished the macrophage and T cell count, the expression of monocyte chemoatlractant protein-1, regulated on activated normal T-cell expressed and secreted (RANTES), and adhesion molecule-1 in the lesions. In addition, cultured vascular smooth muscle cells from both Fc␥R deficient and DKO mice failed to respond to immune complexes, shown by impaired chemokine expression and ⌵F-〉 activation. Furthermore, DKO mice exhibited lack expression of Fc␥RI and Fc␥RIIIA (both activating receptors), while Fc␥RIIB (inhibiting receptor) was potentiated. The authors concluded that Fc␥R deficiency limits development and progression of atherosclerosis, and pointed out the critical role of Fc␥Rs in atherogenesis.
Fc receptors act as trigger molecules for inflammation, allergic, endocytotic, and inhibitory activities of immune effector cells. 17 Recently, specific classes or Fc␥Rs have been well characterized. 18 Two general classes of Fc␥Rs are known, the activating and the inhibitory receptors, which transmit their signals via immunoreceptor typosine-based activation (ITAM) or inhibitory motifs (ITIM). In activating receptors, the ITAM motif can be intrinsic to the receptor, as in Fc␥RIIA (a receptor not found in the mouse), and in Fc␥RI, Fc␥RIIIA, and Fc␥RIV (receptors conserved between mouse and human). The inhibitory receptor (Fc␥RIIB) contains the ITIM sequence, and binds IgG and immune complexes with low affinity. Recently, it has been postulated that Fc␥R activation is involved in a wide range of inflammatory and immune diseases. 18 -21 Accordingly, a novel therapeutic target in atherosclerosis is the Fc␥R.
In previous studies, Fc␥RIIB mediated not only an inhibitory effect on experimental autoimmune myocarditis in rats 13 but also an antiatherosclerotic effect in apo E deficient mice, 15 using the entire immunoglobulin molecule. Specifically, an intact immunoglobulin, but not F(abЈ) 2 fragments of immunoglobulin, inhibited myocarditis or atherosclerosis through the Fc portion. Gill et al 22 demonstrated the targeting effect of immunoglobulin on adhesion molecules using ischemia/reperfusion model in cats, suggesting the downregulation of adhesion molecules via Fc receptors. Recently, it has been shown that Fc receptors play a pivotal role in experimental neointimal vascular hyperplasia via ITIM. 23 Furthermore, Mineo et al demonstrated Fc␥RIIB-mediated C-reactive protein (CRP) inhibition of endothelial nitric oxide (NO) synthase. 24 They found that in control mice, CRP blunts acetylcholine-induced increases in carotid artery vascular conductance, and that, in contrast, CRP enhances a cetylcholine responses in Fc␥RIIB KO mice. 24 
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It is known that FcRIIB is expressed in human endothelial cells and in mouse endothelium, 24 and that CRP levels are strongly correlated with increased risk for myocardial and vascular inflammatory diseases. 25, 26 Based on the current study and also on previously published data, Fc␥IIB blockade may be a novel therapy for inflammatory cardiovascular diseases.
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